Treating Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women
with FDA approved drug can be a great solution in near future! Just a couple of
days ago, in 17 February 2015, Sprout Pharmaceuticals authority announced that
the company has resubmitted an application to the FDA for approval of a
non-hormonal pill “Flibanserin” designed for treatment of Hypoactive Sexual
Desire Disorder (HSDD) in premenopausal women. Flibanserin, if FDA approved,
will be the first treatment for HSDD. The CEO of Sprout Pharmaceuticals, Cindy
Whitehead said, “This NDA re-submission marks the completion of the additional
clinical studies requested by FDA”. Cindy is also expecting the approval will
be in this year.
It is proved that in regulating any sexual desire, our brain plays a
vital role. According to Stephen Stahl, Adjunct Professor of Psychiatry,
University of California San Diego, “The brain plays an important role in
regulating a woman’s sexual desire, and one of the root causes of persistent
and recurrent low sexual desire, or HSDD, stems from an imbalance of
neurotransmitters in the brain”. And this is where Flibanserin can be of great
actions! The studies claim that Flibanserin works against that imbalance and
therefore, provides the right brain chemicals, which help in restoring sexual
desire. There were 3 trials for evaluation of Flibanserin and in all those
trials, the researchers found Flibanserin as a positive one though the drug can
cause few side effects like dizziness, sleepiness and nausea.
So far, as Sprout Pharmaceuticals’ statement, 11,000+ women have been
clinically treated with Flibanserin. If FDA approves, Flibanserin is expected
to be used by many premenopausal women with HSDD.
No comments:
Post a Comment